Patients with active exudative age-related macular degeneration (AMD) are being treated with various treatment regimen, which may include intravitreal ranibizumab (lucentis), bevacizumab (avastin), aflibercept (eylea), etc. Some of these patients do not show benefit from these treatments, including repeat injections in many cases.
The Mediterranean diet may protect against diabetic retinopathy, according to a study published in Diabetes Care. Andrés Díaz-López, from Rovira i Virgili University in Reus, Spain, and colleagues conducted a post hoc analysis of a cohort of patients with type 2 diabetes participating in the PREvención con DIeta MEDiterránea (PREDIMED) study. Patients with type 2 diabetes
READ MORE…
Tracking changes in the eye’s retina may help doctors provide more effective treatment for people with schizophrenia, according to researchers at Rutgers University and Mount Sinai’s New York Eye and Ear Infirmary. A link between vision problems and schizophrenia is well established, with as many as 62 percent of adult patients with schizophrenia experiencing visual
READ MORE…
A new study suggests that the occurrence of advanced forms of a diabetic eye disease remains low among children living with diabetes, regardless of how long they have had the disease or their ability to keep blood sugar levels controlled. Researchers are therefore recommending that most children with type 1 diabetes delay annual diabetic retinopathy screenings
READ MORE…
A multi-institutional team reports that vitamin D may play a significant role in eye health, specifically in the possible prevention of age-related macular degeneration, or AMD, among women who are more genetically prone to developing the sight-damaging disease. In a paper published in JAMA Ophthalmology online, the team found that women who are deficient in
READ MORE…
RetroSense Therapeutics’ Investigational New Drug (IND) application for gene therapy based clinical trial for their product RST-001 has received clearance from the US Food and Drug Administration. RetroSense is developing RST-001 for the treatment of retinitis pigmentosa, a genetic condition that leads to the progressive degeneration of rod and cone photoreceptors (cells found in the retina that sense light),
READ MORE…
A team of researchers at the CHA University in South Korea has successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes of the placenta (AMSCs) into laboratory mice modeled with oxygen-induced retinopathy, which is used to simulate many retinal diseases. The treatment aimed at suppressing abnormal angiogenesis (blood vessel growth) which is recognized
READ MORE…
Extremely preterm infants (<28 weeks’ gestational age) have higher rates of adverse neurodevelopmental outcomes in early childhood than children born at term.
Participants are being enrolled in the first clinical trial that tests the use of retinal progenitor cells to treat retinitis pigmentosa. The product of stem cell research at UCI’s Gavin Herbert Eye Institute and Sue & Bill Gross Stem Cell Research Center, these retinal progenitors are similar to stem cells in terms of potential regenerative
READ MORE…